RBM17 and ovarian cancer: Moreover, SPF45 enhanced fibronectin expression to promote ovarian cancer migration and invasion in a CLK1 phosphorylation-dependent way.46 This finding highlights the potential use of CLK1 inhibitors to dephosphorylate SPF45 in ovarian cancer treatment.